Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.71 |
| ▸ | IDO1 | P14902 | 9/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | CES2 | O00748 | 2/20 | 0.71 |
| ▸ | TDP2 | O95551 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.71 |
| ▸ | CES1 | P23141 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | RECQL | P46063 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | NQO1 | P15559 | 2/20 | 0.71 |
| ▸ | GMNN | O75496 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18790870 | 0.88 | IDO1 (0.71) | MALT1IDO1KDM4EMEN1CES2 | |
| SCHEMBL14236685 | 0.85 | IDO1 (0.57) | MALT1IDO1KDM4EMEN1CES2 | |
| SCHEMBL8260300 | 0.85 | MALT1 (0.54) | MALT1IDO1KDM4EMEN1CES2 | |
| Lapachone SCHEMBL29351050 | 0.83 | MALT1 (1.00) | MALT1IDO1KDM4EMEN1CES2 | |
| Lapachone SCHEMBL107042 | 0.83 | MALT1 (1.00) | MALT1IDO1KDM4EMEN1CES2 | |
| SCHEMBL15109478 | 0.83 | IDO1 (0.59) | MALT1IDO1KDM4EMEN1CES2 | |
| SCHEMBL8370189 | 0.80 | IDO1 (0.55) | MALT1IDO1KDM4EMEN1CES2 | |
| SCHEMBL18791102 | 0.74 | IDO1 (0.56) | MALT1IDO1KDM4EMEN1CES2 | |
| SCHEMBL10141791 | 0.73 | IDO1 (0.55) | MALT1IDO1KDM4EMEN1CES2 | |
| SCHEMBL15034364 | 0.73 | MALT1 (0.76) | MALT1IDO1KDM4EMEN1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4180034-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-9066922-B2 | Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases | MD BIOALPHA CO., LTD. (KR) | 2015-06-30 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | KWAK TAEHWAN (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | KT & G CORPORATION (KR) | 2013-11-14 | — | — | US | disclosed |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | KT & G CO., LTD. (KR) | 2013-09-19 | — | — | US | disclosed |
| WO-2009048251-A2 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2009-04-16 | — | — | WO | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | MD BIOALPHA CO., LTD. (KR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008066295-A1 | PHARMACEUTICAL COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066294-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLE OF NAPHTHOQUINONE-BASED COMPOUND | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066301-A1 | ANTICANCER COMPOSITION CONTAINING NAPHTHOQUINONE-BASED COMPOUND FOR INTESTINE DELIVERY SYSTEM | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066297-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066299-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008066298-A1 | COMPOUND FOR TREATMENT OR PREVENTION OF PROSTATE-RELATED DISEASES AND PHARMACEUTICAL COMPOSITION OF COLON DELIVERY SYSTEM CONTAINING THE SAME | MAZENCE INC. (KR) | 2008-06-05 | — | — | WO | disclosed |
| WO-2007094632-A1 | METHOD FOR CONTROLLING NAD(P)/NAD(P)H RATIO BY OXIDOREDUCTASE | MD BIOALPHA CO., LTD. (KR) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302422-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES | REN, ATP6V1B1, SLC5A1 | MALT1 3646/4885IDO1 1624/4885KDM4E 4046/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | MALT1 3696/4885IDO1 217/4885KDM4E 3868/4885 |
| US-20080146655-A1 | Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases | NDUFAB1, CS, NLN | MALT1 4688/4885IDO1 1806/4885KDM4E 4423/4885 |
| US-20130245111-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES | NLN, SLC25A20, ACAD9 | MALT1 4454/4885IDO1 3300/4885KDM4E 4279/4885 |
| US-20140154319-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CARDIAC DISEASE | TNNT2, TNNC1, TNNI3 | MALT1 3298/4885IDO1 2331/4885KDM4E 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.